Page 2 - Reflections_dyslipidaemia_newsletter4_2023

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #4 2023

Visual abstract Dyslipidaemia

The baseline characteristics of the participants did not differ between the groups, and at randomization, 74% of participants were ≥1
year beyond their initial diagnosis or coronary revascularization.

For the overall study period, in the treat-to-target group, statin intensity was up-titrated in 378 participants (17%), down-titrated in
208 patients (9%) and maintained without changes in 1614 participants (73%). The primary endpoint at three years occurred in
177 participants (8.1%) in the treat-to-target group and 190 participants (8.7%) in the high-intensity statin therapy group (absolute
difference, -0.6 percentage points [upper
boundary of the one-sided 97.5% CI, 1.1
percentage points]; p <0.001 for non-inferiority).

No prespecified secondary endpoints differed
statistically between the groups; however, as a
post-hoc secondary endpoint, a composite of
new-onset diabetes, aminotransferase or creatine
kinase elevation, or end-stage kidney disease
was significantly lower in the treat-to-target group
vs. the high-intensity statin group (6.1% vs. 8.2%;
absolute difference −2.1% [95% CI −3.6% to
−0.5%]; p=0.009).

With regard to the treat-to-target strategy, the
authors comment that the validity of the target
for those with CAD needs to be confirmed. In
the treat-to-target group, the proportion who
met the target was only 56% at one year, 61%

TABLE OF CONTENTS